Advances in Hemophilia A: Future Directions

Learn the rationale and efficacy and safety data for emerging extended half-life factor replacement and nonfactor replacement strategies for hemophilia A, including mimetics, rebalancers, and gene therapy.
Michael Callaghan, MD
Stacy Croteau Headshot
Stacy E. Croteau, MD, MMS
person default
Cindy A. Leissinger, MD
Guy A. Young, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.57 MB
Released: December 5, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Genentech

Related Content

Downloadable slides with expert recommendations on the integration of oncology biosimilars into clinical practice from Clinical Care Options.

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP Released: April 20, 2020

Downloadable slides with expert recommendations on the management of patients with acute and chronic graft versus host disease (GVHD) from Clinical Care Options.

Corey S. Cutler, MD, MPH, FRCPC Released: April 13, 2020

Clinical Care Options (CCO) downloadable resource guide for the optimal management of patients with graft-vs-host disease (GVHD).

Released: April 10, 2020

Review key data in hematologic malignancies and nonmalignant hematologic disorders from ASH 2019 with these CME-certified expert commentaries from CCO

Hanny Al-Samkari, MD Rami S. Komrokji, MD Sagar Lonial, MD Jeff P. Sharman, MD Sujit Sheth, MD Eunice S. Wang, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 17, 2020 Expired: March 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue